Alcon To Keep R&D Focus After Spin-Off From Parent Nestle By April Via IPO
This article was originally published in The Gray Sheet
Executive Summary
Alcon plans to spend $1.4 bil. on research and development over the next four years as an independent company, following its spin-off from Nestle
You may also be interested in...
Ophthalmic Spin-Offs Alcon, AMO See Stock Gains In 2002, Join MDDI Index
Ophthalmic device makers Alcon and Advanced Medical Optics (AMO) were both able to achieve double-digit stock price percentage gains in 2002 after debuting as independent firms, in part due to expanding sales of surgical products such as IOLs
Ophthalmic Spin-Offs Alcon, AMO See Stock Gains In 2002, Join MDDI Index
Ophthalmic device makers Alcon and Advanced Medical Optics (AMO) were both able to achieve double-digit stock price percentage gains in 2002 after debuting as independent firms, in part due to expanding sales of surgical products such as IOLs
Financings In Brief
Alcon IPO: Swiss eye care company reports sales of $707 mil., up 8%, in its first quarter as an independent entity following its March 20 initial public offering of 76.7 mil. shares of common stock at $33 each - which raised net proceeds of roughly $2.4 bil. (1"The Gray Sheet" March 4, 2002, p. 22). Surgical unit revenue of $338 mil. was ahead 4%, anchored by AcrySof intraocular lens sales of $102 mil...